ABY-1G5

**ABY-1G5** is an investigational anti-amyloid beta monoclonal antibody being developed by Abyssinia Biologics for Alzheimer's disease and related neurodegenerative conditions. Available public information indicates that it is designed to bind toxic, soluble oligomeric amyloid beta species rather than broadly targeting all amyloid deposits, and it has been described as having potential use both as a plasma-based diagnostic reagent and as an immunotherapeutic candidate. Public pipeline sources place the program in preclinical development, with reported target assignment to amyloid beta precursor protein biology and amyloid beta oligomers in the context of Alzheimer's disease.